Tenax Therapeutics is trading 14.08% down at $1.83 after Guggenheim downgraded the stock from Buy to Neutral on August 31, 2026, citing uncertainty around LEVEL trial efficacy and regulatory approval.
- The downgrade followed additional subgroup data presented at the European Society of Cardiology conference.
- Coverage confirms the action was linked to new clinical data and ongoing uncertainty surrounding the late-stage program.